logo

For the Inventor, By the Inventor

Oklahoma City, OK, United States of America

Oklahoma Medical Research Foundation


USPTO Granted Patents = 197



Trademarks = 2

Forward Citations = 1,912

Loading Chart...
Loading Chart...

211 inventors (with patents filed for the assignee):

goldMedal Charles T Esmon (29 out of 29 patents)

silverMedal Robert A Floyd (24 out of 28 patents)

bronzeMedal John M Carney (12 out of 21 patents)

4.  Rheal A Towner (11 out of 11 patents)

5.  John B Harley (11 out of 14 patents)

6.  Peter J Sims (11 out of 15 patents)

7.  Judith Ann James (11 out of 12 patents)

8.  Rodger P McEver (10 out of 33 patents)

9.  Jordan J Tang (10 out of 10 patents)

10.  James H Morrissey (8 out of 28 patents)

11.  Jordan J N Tang (8 out of 9 patents)

12.  Carl V Manion (8 out of 9 patents)

13.  Arun K Ghosh (7 out of 54 patents)

14.  Lijun Xia (7 out of 7 patents)

15.  Jun Xu (7 out of 7 patents)


Core Competencies:
DNA Methylation
Sjogren's Syndrome
Monoclonal Antibodies
Systemic Lupus Erythematosus
Multiple Sclerosis
Gliomas Treatment
Fucosylation
Acute Acoustic Trauma
Thrombotic Conditions
Stem Cell Therapy
Biomarkers
Protein Trafficking

197 patents:

1. 12467092 - Peripheral blood DNA methylation models as predictors of knee osteoarthritis radiographic progression (2025-11-11),
2. 12415851 - Monoclonal antibodies to ELTD1 and uses thereof (2025-09-16),
3. 12414979 - Compositions and methods for treating Sjogren's syndrome (2025-09-16),
4. 12352749 - Humanantibodies and uses therefor (2025-07-08),
5. 12140592 - Biomarkers for assessing risk of transitioning to systemic lupus erythematosus classification and disease pathogenesis (2024-11-12),
6. 12031136 - Treatment for skeletal diseases caused by intracellular protein trafficking defects (2024-07-09),
7. 12030950 - Treatment of multiple sclerosis and neuromyelitis optica (2024-07-09),
8. 11752122 - N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated TGF-beta activation and signaling (2023-09-12),
9. 11740248 - Biomarkers for assessing subjects with multiple sclerosis (2023-08-29),
10. 11660280 - Treatment of drug resistant gliomas (2023-05-30),
11. 11585810 - Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare (2023-02-21),
12. 11567077 - Humanantibodies and uses therefor (2023-01-31),
13. 11458187 - Extracellular histones as biomarkers for prognosis and molecular targets for therapy (2022-10-04),
14. 11300575 - Biomarkers and methods for measuring and monitoring inflammatory disease activity (2022-04-12),
15. 11084852 - Ubiquitin interacting motif peptides as therapeutics (2021-08-10),
The Oklahoma Medical Research Foundation (OMRF) is an independent, nonprofit biomedical research institute located in Oklahoma City, Oklahoma. With a mission to understand and cure human diseases, OMRF conducts groundbreaking research in areas such as cancer, cardiovascular disease, autoimmune disorders, and aging. Through collaboration with scientists worldwide, OMRF aims to improve the health and quality of life for people everywhere.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
197 Patents

#1 in Oklahoma City, OK

#7 in Oklahoma

#2,016 in US

#4,156 in the World

...
Oklahoma City, OK, United States of America

Oklahoma Medical Research Foundation

Forward Citations = 1,912

211 inventors:

goldMedal Charles T Esmon (29 out of 29 patents)

silverMedal Robert A Floyd (24 out of 28 patents)

bronzeMedal John M Carney (12 out of 21 patents)

4.  Rheal A Towner (11 out of 11 patents)

5.  John B Harley (11 out of 14 patents)

Please report any incorrect information to support@idiyas.com
Loading…